Approaches to the treatment of pancreatic carcinoma.
Explore the source record for details and available documents.
Adenocarcinoma↗
Biomedical subjects
M S Aapro
Publications and source records attributed to M S Aapro.
In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
The in vitro antiproliferative effect of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin was assessed in a range of human tumour types, including 25 tumour cell lines and 35 primary cultures. Additionally, 12 human normal bone marrow samples were analyzed. Seven laboratories, all members of the EORTC Preclinical Therapeutic Models Group (PTMG), have performed these tests, using their own individual assay procedures. In all comparisons docetaxel and paclitaxel were much more potent than cisplatin with IC50 values of the taxoids being in the nanomolar range. Docetaxel generally was two- to four-fold more cytotoxic than paclitaxel. The sensitivity profile of the cell lines, which was based on the IC50 values, indicated a certain degree of cross-sensitivity between paclitaxel and docetaxel (linear regression analysis; r = 0.73, p < 0.001). On the other hand, the sensitivity profile of cisplatin was different from the ones seen for docetaxel and paclitaxel, indicating that no cross-sensitivity exists between cisplatin and both taxoids.
Antineoplastic Agents, Phytogenic↗
Combined chemoradiotherapy for invasive bladder cancer: a feasibility approach in a non selected population.
BACKGROUND: We aimed to evaluate the tolerance and response rate to neo-adjuvant combined chemo-radiotherapy and to determine the possibilities of conservative treatment in patients (pts) with muscle invasive bladder cancer. METHODS: Thirty-nine T1-4, NO-3 pts were enrolled in this study. After 2 cycles of treatment, responders at intermediate assessment were treated by either additional chemotherapy +/- radiotherapy or radical cystectomy. If there was evidence of persistent tumour, radical cystectomy was performed whenever possible. RESULTS: Thirty-five (90%) pts completed the pre-operative treatment, 26/39 (67%) were in remission at intermediate assessment and 8 of them underwent a radical cystectomy. The median follow-up was 87 months, and 15 pts are alive without evidence of tumour and 5 with bladder preservation. The 3 and 5-year survival was 51 and 40%, respectively. Median survival differences between the responding operated or non-operated pts were not statistically different. CONCLUSIONS: Neo-adjuvant chemo-radiotherapy for invasive bladder cancer is effective with acceptable toxicity, and inoperable patients can benefit from such treatment.
Adult↗